Empacrux L 10mg/5mg Tablet

The Empacrux L 10mg/5mg tablet is a combination medication containing two active ingredients: Empagliflozin (10 mg) and Linagliptin (5 mg). It is primarily used for the treatment of type 2 diabetes mellitus in adults when diet and exercise alone are insufficient to control blood sugar levels. Below is a detailed product description based on available information:

Product Description

• Composition: Each film-coated tablet contains:
  • Empagliflozin: 10 mg (an SGLT-2 inhibitor)
  • Linagliptin: 5 mg (a DPP-4 inhibitor)
• Appearance: Typically a round, biconvex, pink film-coated tablet (appearance may vary by manufacturer).
• Therapeutic Use: Empacrux L is indicated for adults with type 2 diabetes mellitus to improve glycemic control, either alone or in combination with other antidiabetic medications, when diet and exercise are inadequate. It may also reduce the risk of cardiovascular events in patients with type 2 diabetes and established heart disease.
• Mechanism of Action:
  • Empagliflozin: Inhibits sodium-glucose co-transporter 2 (SGLT-2) in the kidneys, reducing glucose reabsorption and promoting its excretion through urine, thus lowering blood sugar levels. It also aids in weight reduction and may lower the risk of cardiovascular death.
  • Linagliptin: Inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that breaks down incretin hormones (GLP-1 and GIP). This increases insulin secretion and reduces glucagon levels in a glucose-dependent manner, helping to control blood sugar.
• Dosage and Administration:
  • The usual dose is one tablet taken orally once daily, with or without food, as prescribed by a healthcare provider.
  • Swallow the tablet whole with water; do not crush, chew, or break it.
  • Dosage adjustments may be needed based on kidney function or other medical conditions.
• Side Effects: Common side effects may include:
  • Urinary tract infections
  • Genital mycotic infections (e.g., vaginal yeast infections)
  • Dehydration (due to increased urination)
  • Hypoglycemia (especially when combined with other diabetes medications)
  • Nasopharyngitis
  • Acute kidney injury (rare, monitor kidney function)
  • Less common but serious side effects include ketoacidosis, severe allergic reactions, or pancreatitis.
• Precautions:
  • Monitor kidney function regularly, as Empagliflozin may affect renal health.
  • Stay well-hydrated to prevent dehydration.
  • Not suitable for patients with type 1 diabetes or diabetic ketoacidosis.
  • Avoid excessive alcohol consumption, as it may increase the risk of side effects.
  • Inform your doctor if you have a history of kidney, liver, or heart disease, or if you are pregnant or breastfeeding
  • Storage:
    • Store at room temperature (15–30°C) in a dry place, away from heat, moisture, and direct light.
    • Keep out of reach of children and pets.
  • Contraindications:
    • Hypersensitivity to Empagliflozin, Linagliptin, or any tablet components.
    • Severe renal impairment or end-stage renal disease.
    • Type 1 diabetes or diabetic ketoacidosis.
  • Overdose:
    • An overdose may lead to severe hypoglycemia, dehydration, or acidosis.
    • Seek immediate medical attention. Treatment may involve supportive measures like sodium bicarbonate for acidosis and monitoring in a hospital setting.

    • Important Notes

    • Always take Empacrux L under medical supervision and follow your doctor’s instructions.
    • Regular blood sugar monitoring is essential while using this medication.
    • Maintain good hygiene to prevent infections, especially genital or urinary tract infections.
    • Consult your healthcare provider before starting or stopping this medication, especially if combining it with other drugs.